Technical Analysis for MRUS - Merus N.V.

Grade Last Price % Change Price Change
grade B 16.825 1.11% 0.19
MRUS closed up 1.11 percent on Tuesday, September 17, 2019, on 7.75 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Flat
See historical MRUS trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Fell Below 20 DMA Bearish 1.11%
MACD Bearish Signal Line Cross Bearish 1.11%
NR7 Range Contraction 1.11%
Down 3 Days in a Row Weakness 1.11%
Down 4 Days in a Row Weakness 1.11%

Older signals for MRUS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Medicine Health Immunology Solid Tumors Antibodies Monoclonal Antibodies Cancer Immunotherapy Acute Myeloid Leukemia Myelodysplastic Syndrome Monoclonal Antibody Therapy Ovarian Cancers Europe
Is MRUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.95
52 Week Low 11.0
Average Volume 47,520
200-Day Moving Average 14.0934
50-Day Moving Average 16.1067
20-Day Moving Average 16.6528
10-Day Moving Average 16.8055
Average True Range 0.9718
ADX 26.3
+DI 23.4842
-DI 13.2357
Chandelier Exit (Long, 3 ATRs ) 15.9046
Chandelier Exit (Short, 3 ATRs ) 17.9654
Upper Bollinger Band 18.2929
Lower Bollinger Band 15.0127
Percent B (%b) 0.55
BandWidth 19.697588
MACD Line 0.2147
MACD Signal Line 0.2295
MACD Histogram -0.0148
Fundamentals Value
Market Cap 326.34 Million
Num Shares 19.4 Million
EPS -5.48
Price-to-Earnings (P/E) Ratio -3.07
Price-to-Sales 36.17
Price-to-Book 3.52
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.80
Resistance 3 (R3) 17.80 17.48 17.64
Resistance 2 (R2) 17.48 17.23 17.48 17.58
Resistance 1 (R1) 17.15 17.08 17.32 17.15 17.53
Pivot Point 16.83 16.83 16.91 16.83 16.83
Support 1 (S1) 16.50 16.58 16.67 16.50 16.12
Support 2 (S2) 16.18 16.43 16.18 16.07
Support 3 (S3) 15.85 16.18 16.01
Support 4 (S4) 15.85